About Us
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries.
Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups and other stakeholders, to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with ten patent holders for thirteen HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals and a tuberculosis treatment. MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC).
MPP in Numbers
patent holders with MPP signed agreements
generic manufacturers and product developers have sublicences from MPP
countries have benefitted from access to MPP-licensed products
ongoing pharmaceutical development projects
Billion dollars saved by the international community, from January 2012 to June 2020
Billion doses of treatment supplied from January 2012 to June 2020
Million patient-years of treatment through MPP’s generic partners, from January 2012 to June 2020
For Everyone Everywhere
Discover where we helped and what we have achieved
Key Publications
Annual Reports
06 October 2020
Twitter Feed
MedicinesPatentPool @MedsPatentPool
🗞️"MPP’s generic manufacturing partners in action" newsletter is out! Scan through the latest: ✅ quarterly filing analysis & regulatory approvals ✅ key policy updates & MPP news ✅ interview of @AurobindoO's Umesh K ➡️https://t.co/hypxkbrFoN #GlobalHealth #UHC #Access2Meds
MedicinesPatentPool @MedsPatentPool
Big news at #UnionConf: 1st identification of shorter drug-suceptible #TB treatment since 1980s. Huge potential for convenience, adherence, reduction in onward transmission & resistance. Historically, it has taken us half a century to reduce treatment course from 18 months to 6! https://t.co/vMZfkq015F
MedicinesPatentPool @MedsPatentPool
“20 years ago, #TB activism was mostly non-existent, treatments were ancient & programmes underfunded. But since then things have changed for better.” Check out our latest story @VandeveldeWim on how #communities are driving the fight to #EndTB #UnionConf https://t.co/k24RuxMPmb https://t.co/NBlXdwSOcp
MedicinesPatentPool @MedsPatentPool
MPP is proud to be attending the 51st #UnionConf on #LungHealth & looks forward to new research insights 🫁 & through-provoking discussions around #prevention, #MDRTB, #treatments, #accessToMedicines, #paediatric #TB, #TBAction and much more! Stay tuned! https://t.co/WuKiJNiuoj
MedicinesPatentPool @MedsPatentPool
📢NEWS from #MedsPaL: #Patent status information on five #TB drug candidates - OPC-167832, Telacebec (Q203), GSK3036656, Delpazolid (LCB01-371), BTZ-043, currently in clinical trials related to #tuberculosis, is now on #MedsPaL. Check out 👉 https://t.co/8ycHLvVi44 #UnionConf https://t.co/im9zIO4Kco
Unitaid @UNITAID
This report is an important step toward using innovation to address the unique needs of the most vulnerable population. We encourage all stakeholders, notably manufacturers & developers to support all steps towards prompt development of the needed products https://t.co/FKoNMYTBSA https://t.co/DY0LuwevBQ
